TGTX - TG Therapeutics Stock Price, News & Analysis

$7.65 0.30 (4.08 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$7.35
Today's Range$7.70 - $7.25
52-Week Range$4.10 - $15.35
Volume680,796 shs
Average Volume1.57 million shs
Market Capitalization$540.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.25

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:TGTX
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio4.94%
Quick Ratio4.94%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales3,603.15
Cash FlowN/A
Price / CashN/A
Book Value$1.13 per share
Price / Book6.77

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.93)
Net Income$-78,250,000.00
Net Margins-73,217.77%
Return on Equity-151.21%
Return on Assets-116.84%

Miscellaneous

Employees64
Outstanding Shares70,650,000

Frequently Asked Questions for TG Therapeutics (NASDAQ:TGTX)

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.05. The biopharmaceutical company earned $0.04 million during the quarter, compared to analysts' expectations of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. View TG Therapeutics' Earnings History.

Where is TG Therapeutics' stock going? Where will TG Therapeutics' stock price be in 2017?

9 equities research analysts have issued twelve-month target prices for TG Therapeutics' stock. Their forecasts range from $23.00 to $33.00. On average, they anticipate TG Therapeutics' stock price to reach $28.63 in the next year. View Analyst Ratings for TG Therapeutics.

What are Wall Street analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:

  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (8/12/2017)
  • 2. FBR & Co analysts commented, "On the morning of March 6, TG Therapeutics announced positive top-line data from its Phase III GENUINE study of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high-risk chronic lymphocytic leukemia (CLL). The study met its primary endpoint, with an overall response rate (ORR) of 80% in the combination of TG-1101 plus ibrutinib compared to ibrutinib alone in treated patients. The GENUINE Phase III study is a randomized, open-label multi-center trial that is being conducted to evaluate the safety and efficacy of TG-1101 plus ibrutinib compared to ibrutinib alone that has enrolled 126 adult patients with high-risk CLL across 160 clinical sites in the U.S. and Israel. In the study, high risk was defined as patients with one or more of the following: 17p deletion, 11q deletion, or p53 mutation. We believe the top-line data from the study are highly compelling and look forward to the full data set, which the company is targeting to present at a medical meeting in 1H17. The company plans to meet with the FDA to discuss the results and filing for accelerated approval in 2H17." (3/6/2017)

Are investors shorting TG Therapeutics?

TG Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totalling 17,557,367 shares, an increase of 16.3% from the October 13th total of 15,097,551 shares. Based on an average daily trading volume, of 2,154,519 shares, the days-to-cover ratio is presently 8.1 days. Currently, 32.2% of the company's stock are sold short.

Who are some of TG Therapeutics' key competitors?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:

  • Michael S. Weiss, Executive Chairman of the Board, President, Chief Executive Officer (Age 51)
  • Sean A. Power CPA, Chief Financial Officer, Treasurer, Corporate Secretary (Age 35)
  • Laurence Neil Charney, Independent Director (Age 70)
  • Yann Echelard, Independent Director (Age 53)
  • Kenneth Hoberman, Independent Director (Age 52)
  • Daniel Hume, Independent Director (Age 51)
  • William J. Kennedy Ph.D., Independent Director (Age 71)

Who owns TG Therapeutics stock?

TG Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Columbus Circle Investors (2.23%), Jennison Associates LLC (1.81%), Artal Group S.A. (0.58%), JPMorgan Chase & Co. (0.52%), Schwab Charles Investment Management Inc. (0.34%) and Ameriprise Financial Inc. (0.26%). Company insiders that own TG Therapeutics stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.

Who sold TG Therapeutics stock? Who is selling TG Therapeutics stock?

TG Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Artal Group S.A., Ameriprise Financial Inc., Stoneridge Investment Partners LLC, Russell Investments Group Ltd., California State Teachers Retirement System and JPMorgan Chase & Co.. Company insiders that have sold TG Therapeutics company stock in the last year include Laurence N Charney, Sean A Power and William James Kennedy. View Insider Buying and Selling for TG Therapeutics.

Who bought TG Therapeutics stock? Who is buying TG Therapeutics stock?

TG Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Columbus Circle Investors, Hikari Power Ltd, Raymond James Financial Services Advisors Inc., Sectoral Asset Management Inc and Swiss National Bank. View Insider Buying and Selling for TG Therapeutics.

How do I buy TG Therapeutics stock?

Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TG Therapeutics stock can currently be purchased for approximately $7.65.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $540.49 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-78,250,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. TG Therapeutics employs 64 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 Gansevoort St Fl 9, NEW YORK, NY 10014-1667, United States. The biopharmaceutical company can be reached via phone at +1-212-5544484 or via email at [email protected]


MarketBeat Community Rating for TG Therapeutics (TGTX)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for TG Therapeutics (NASDAQ:TGTX)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.622.622.693.00
Ratings Breakdown: 2 Sell Ratings
1 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings
2 Sell Ratings
1 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings
1 Sell Ratings
2 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings
0 Sell Ratings
0 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings
Consensus Price Target: $25.04$23.67$23.67$24.84
Price Target Upside: 203.47% upside155.23% upside101.47% upside121.79% upside

Consensus Price Target History for TG Therapeutics (NASDAQ:TGTX)

Price Target History for TG Therapeutics (NASDAQ:TGTX)

Analysts' Ratings History for TG Therapeutics (NASDAQ:TGTX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017HC WainwrightReiterated RatingBuy -> Buy$18.00 -> $33.00N/AView Rating Details
10/3/2017SunTrust Banks, Inc.Reiterated RatingBuy$28.00MediumView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
6/5/2017Jefferies Group LLCReiterated RatingBuy$23.00MediumView Rating Details
4/21/2017Raymond James Financial, Inc.Reiterated RatingBuyHighView Rating Details
3/8/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$30.00LowView Rating Details
3/7/2017Langenberg & CompanyBoost Price TargetPositive$28.00 -> $30.00N/AView Rating Details
2/22/2017AegisInitiated CoverageBuy$26.00N/AView Rating Details
12/7/2016Roth CapitalSet Price TargetBuy$33.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
8/24/2016S&P Equity ResearchLower Price Target$7.15 -> $6.40N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for TG Therapeutics (NASDAQ:TGTX)

Earnings by Quarter for TG Therapeutics (NASDAQ:TGTX)

Earnings History by Quarter for TG Therapeutics (NASDAQ TGTX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.43)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.45)$0.04 million$0.04 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.42)($0.52)$0.04 million$0.04 millionViewN/AView Earnings Details
11/7/2016Q3($0.31)($0.50)$0.04 million$0.04 millionViewListenView Earnings Details
8/8/2016Q2($0.29)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
5/10/2016Q1($0.36)($0.28)$0.04 million$0.04 millionViewListenView Earnings Details
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details
11/9/2015Q3($0.34)($0.28)$0.04 million$0.04 millionViewN/AView Earnings Details
8/10/2015Q215($0.32)($0.38)$0.22 million$0.04 millionViewListenView Earnings Details
5/4/2015Q115($0.33)($0.39)$0.04 million$0.04 millionViewN/AView Earnings Details
3/11/2015Q414($0.26)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
11/10/2014Q214($0.32)($0.51)$0.04 million$0.04 millionViewN/AView Earnings Details
7/21/2014($0.28)($0.36)$0.04 million$0.04 millionViewN/AView Earnings Details
5/12/2014Q114($0.19)($0.25)$0.04 million$0.04 millionViewN/AView Earnings Details
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TG Therapeutics (NASDAQ:TGTX)
2017 EPS Consensus Estimate: ($1.79)
2018 EPS Consensus Estimate: ($1.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.48)($0.47)($0.48)
Q2 20173($0.45)($0.37)($0.41)
Q3 20173($0.50)($0.40)($0.45)
Q4 20173($0.46)($0.43)($0.45)
Q1 20181($0.48)($0.48)($0.48)
Q2 20181($0.48)($0.48)($0.48)
Q3 20181($0.50)($0.50)($0.50)
Q4 20181($0.51)($0.51)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TG Therapeutics (NASDAQ:TGTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TG Therapeutics (NASDAQ TGTX)

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 48.23%
Insider Trades by Quarter for TG Therapeutics (NASDAQ:TGTX)
Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Insider Trades by Quarter for TG Therapeutics (NASDAQ TGTX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/19/2017Sean A PowerCFOSell59,976$11.09$665,133.84View SEC Filing  
4/11/2017William James KennedyDirectorSell8,548$10.27$87,787.96View SEC Filing  
4/4/2017Laurence N. CharneyDirectorSell7,000$11.17$78,190.00View SEC Filing  
1/4/2017Sean A. PowerCFOSell8,816$4.55$40,112.80View SEC Filing  
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TG Therapeutics (NASDAQ TGTX)

Source:
DateHeadline
Today’s Research Reports on Trending Tickers: MannKind Corporation and TG TherapeuticsToday’s Research Reports on Trending Tickers: MannKind Corporation and TG Therapeutics
finance.yahoo.com - November 22 at 9:58 AM
PAREXEL International (PRXL) vs. TG Therapeutics (TGTX) Head-To-Head ReviewPAREXEL International (PRXL) vs. TG Therapeutics (TGTX) Head-To-Head Review
www.americanbankingnews.com - November 14 at 1:36 PM
TG Therapeutics, Inc. (TGTX) Given "Buy" Rating at HC WainwrightTG Therapeutics, Inc. (TGTX) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - November 14 at 8:46 AM
TG Therapeutics, Inc. Expected to Post FY2017 Earnings of ($1.77) Per Share (TGTX)TG Therapeutics, Inc. Expected to Post FY2017 Earnings of ($1.77) Per Share (TGTX)
www.americanbankingnews.com - November 13 at 1:50 AM
TG Therapeutics, Inc. (TGTX) to Post FY2017 Earnings of ($1.91) Per Share, SunTrust Banks ForecastsTG Therapeutics, Inc. (TGTX) to Post FY2017 Earnings of ($1.91) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - November 13 at 1:49 AM
TG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from BrokeragesTG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 8:13 PM
TG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from BrokeragesTG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 8:13 PM
TG Therapeutics (TGTX) CEO Michael Weiss on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaTG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 12 at 8:22 AM
TG Therapeutics, Inc. (TGTX) Short Interest UpdateTG Therapeutics, Inc. (TGTX) Short Interest Update
www.americanbankingnews.com - November 11 at 1:50 AM
TG Therapeutics, Inc. (TGTX) Releases  Earnings Results, Misses Estimates By $0.05 EPSTG Therapeutics, Inc. (TGTX) Releases Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - November 9 at 7:46 PM
TG Therapeutics (TGTX) PT Raised to $36 at SunTrust Robinson Humphrey; Catalyst Rich 6-18 Months - StreetInsider.comTG Therapeutics (TGTX) PT Raised to $36 at SunTrust Robinson Humphrey; Catalyst Rich 6-18 Months - StreetInsider.com
www.streetinsider.com - November 9 at 3:30 PM
Zacks: Brokerages Anticipate TG Therapeutics, Inc. (TGTX) Will Post Earnings of -$0.48 Per ShareZacks: Brokerages Anticipate TG Therapeutics, Inc. (TGTX) Will Post Earnings of -$0.48 Per Share
www.americanbankingnews.com - November 9 at 10:31 AM
TG Therapeutics, Inc. Provides Business Update and Reports Third ... - GlobeNewswire (press release)TG Therapeutics, Inc. Provides Business Update and Reports Third ... - GlobeNewswire (press release)
globenewswire.com - November 9 at 8:04 AM
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial ResultsTG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 8:04 AM
TG Therapeutics reports 3Q lossTG Therapeutics reports 3Q loss
finance.yahoo.com - November 9 at 8:04 AM
Edited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 8:04 AM
Financial Analysis: TG Therapeutics (TGTX) vs. Its PeersFinancial Analysis: TG Therapeutics (TGTX) vs. Its Peers
www.americanbankingnews.com - November 7 at 2:06 PM
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update - GlobeNewswire (press release)TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update - GlobeNewswire (press release)
globenewswire.com - November 6 at 8:08 AM
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business UpdateTG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update
finance.yahoo.com - November 6 at 8:08 AM
TG Therapeutics (TGTX) Presents On 2017 Post ECTRIMS - ACTRIMS - SlideshowTG Therapeutics (TGTX) Presents On 2017 Post ECTRIMS - ACTRIMS - Slideshow
seekingalpha.com - November 5 at 7:05 AM
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual ... - GlobeNewswire (press release)TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual ... - GlobeNewswire (press release)
globenewswire.com - November 2 at 9:48 AM
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual MeetingTG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 2 at 9:48 AM
TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 ... - GlobeNewswire (press release)TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 ... - GlobeNewswire (press release)
globenewswire.com - October 31 at 10:33 AM
TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple SclerosisTG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis
finance.yahoo.com - October 31 at 10:32 AM
TG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 ... - StreetInsider.comTG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 ... - StreetInsider.com
www.streetinsider.com - October 27 at 9:25 PM
TG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at ECTRIMS - ACTRIMSTG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at ECTRIMS - ACTRIMS
www.streetinsider.com - October 27 at 4:20 PM
TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS MeetingTG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - October 27 at 4:20 PM
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS - StreetInsider.comTG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS - StreetInsider.com
www.streetinsider.com - October 26 at 11:47 AM
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS MeetingTG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - October 26 at 11:47 AM
Commit To Buy TG Therapeutics At $5, Earn 21% Using OptionsCommit To Buy TG Therapeutics At $5, Earn 21% Using Options
www.thestreet.com - October 25 at 9:07 PM
TG Therapeutics (TGTX) versus Its Competitors Critical AnalysisTG Therapeutics (TGTX) versus Its Competitors Critical Analysis
www.americanbankingnews.com - October 25 at 4:26 AM
$40,000.00 in Sales Expected for TG Therapeutics, Inc. (TGTX) This Quarter$40,000.00 in Sales Expected for TG Therapeutics, Inc. (TGTX) This Quarter
www.americanbankingnews.com - October 22 at 5:30 AM
TG Therapeutics, Inc. (TGTX) Receives Average Recommendation of "Buy" from AnalystsTG Therapeutics, Inc. (TGTX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 18 at 11:02 PM
TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS Meeting - GlobeNewswire (press release)TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS Meeting - GlobeNewswire (press release)
globenewswire.com - October 18 at 9:29 AM
Oversold Conditions For TG Therapeutics - NasdaqOversold Conditions For TG Therapeutics - Nasdaq
www.nasdaq.com - October 18 at 9:29 AM
TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 TrialTG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial
finance.yahoo.com - October 17 at 8:00 AM
TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 TrialTG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial
finance.yahoo.com - October 17 at 8:00 AM
TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS MeetingTG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - October 17 at 8:00 AM
TG Therapeutics, Inc. (TGTX) Cut to "Sell" at ValuEngineTG Therapeutics, Inc. (TGTX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - October 16 at 10:36 PM
TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : October 12, 2017TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : October 12, 2017
finance.yahoo.com - October 13 at 9:17 AM
Biotech Stock Performance Review -- Cyclacel Pharma, TG Therapeutics, Vericel, and Achaogen - PR Newswire (press release)Biotech Stock Performance Review -- Cyclacel Pharma, TG Therapeutics, Vericel, and Achaogen - PR Newswire (press release)
www.prnewswire.com - October 9 at 8:19 AM
TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development - GlobeNewswire (press release)TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development - GlobeNewswire (press release)
globenewswire.com - October 6 at 3:38 PM
TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical DevelopmentTG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development
finance.yahoo.com - October 6 at 11:17 AM
TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : September 27, 2017TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : September 27, 2017
finance.yahoo.com - October 3 at 1:30 PM
TG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : September 28, 2017TG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : September 28, 2017
finance.yahoo.com - October 3 at 1:30 PM
TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS)TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS)
finance.yahoo.com - October 3 at 1:30 PM
Why You Need To Look At This Factor Before Buying TG Therapeutics Inc (TGTX)Why You Need To Look At This Factor Before Buying TG Therapeutics Inc (TGTX)
finance.yahoo.com - October 3 at 1:30 PM
TG Therapeutics, Inc. (TGTX) Expected to Post Earnings of -$0.46 Per ShareTG Therapeutics, Inc. (TGTX) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - October 1 at 10:26 PM
UPDATE: TG Therapeutics (TGTX) Secures Grant from National Multiple Sclerosis Society to Support Development of ... - StreetInsider.comUPDATE: TG Therapeutics (TGTX) Secures Grant from National Multiple Sclerosis Society to Support Development of ... - StreetInsider.com
www.streetinsider.com - September 30 at 2:11 PM
TG Therapeutics (TGTX) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowTG Therapeutics (TGTX) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 5:32 AM

Social Media

Financials

Chart

TG Therapeutics (NASDAQ TGTX) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.